BackBeauty Health Company (The) Overview
Beauty Health Company (The) - Ordinary Shares - Class A

Beauty Health Company (The) Return on Equity

Beauty Health Company (The) (SKIN) has a ROE of 240.75%, above the Healthcare sector average of 22.01%.

Get informed when a big investor buys or sells

+ Follow

ROE

240.75%

Return on Equity

240.75%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Beauty Health Company (The) (SKIN) FAQ

Beauty Health Company (The)'s return on equity stands at 240.75%. That is above the Healthcare sector average of 22.01%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Beauty Health Company (The) sits higher the Healthcare benchmark (22.01%) with a ROE of 240.75%. That is roughly 993.8% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of 240.75% for Beauty Health Company (The) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Beauty Health Company (The)'s ROE evolved across reporting periods, while the comparison chart places SKIN next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, ROE is commonly used to spot outliers. Beauty Health Company (The)'s reading of 240.75% (sector avg 22.01%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.